Trial record 12 of 31 for:    "Antiphospholipid syndrome"

Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Woman's Health University Hospital, Egypt.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
alaa eldeen mahmoud ismail, Woman's Health University Hospital, Egypt
ClinicalTrials.gov Identifier:
NCT01661439
First received: July 25, 2012
Last updated: June 20, 2014
Last verified: March 2012
  Purpose

Preconceptional use of low molecular weight heparin (enoxaparin) and aspirin in patient with recurrent miscarriages with positive anti phospholipid antibodies increase the implantation rate and the duration of pregnancy with low complications to the mother and the baby.


Condition Intervention
Recurrent Pregnancy Losses
Positive Anti Phospholipid Syndrome
Drug: low molecular weight heparin (enoxeparine)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)

Resource links provided by NLM:


Further study details as provided by Woman's Health University Hospital, Egypt:

Primary Outcome Measures:
  • Pregnancy continuation beyond twelve weeks gestation [ Time Frame: ONE YEAR ] [ Designated as safety issue: Yes ]
    giving low molecular weight heparin (enoxaparin) and 81 mg aspirin in patients with positive anti phospholipid antibodies with history of recurrent miscarriages or intrauterine fetal deaths in the preconceptional period one month before pregnancy with follow up as regarding the clinical pregnancy rate,the rate of continuation of pregnancy beyond 28 weeks gestation and the complications related to long term use of heparin and the severity of complication of APS in comparison to the traditional use of anticoagulant after documentation of the fetal heart rate


Estimated Enrollment: 316
Study Start Date: March 2012
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Low molecular weight heparin
SC LMWH IN patients with recurrent pregnancy loss
Drug: low molecular weight heparin (enoxeparine)
1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
Other Name: clexane,innohep

Detailed Description:

Preconceptional heparin during follicular or luteal phase,improves the implantation rate by increasing the blood flow and increasing the implantation factors,also decreasing the pregnancy complication resulting from Antiphospholipid Syndrome (APS).

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

patients with recurrent pregnancy losses either two or more recurrent miscarriages or intrauterine fetal deathes after 20 weeks of gestation with positive antiphospholipid antibodies in medium to high titer in two occasions 6 weeks apart.

Criteria

Inclusion Criteria:

  1. All women with recurrent first-trimester miscarriage and all women with one or more second-trimester miscarriage who screened before pregnancy for antiphospholipid antibodies.
  2. To diagnose antiphospholipid syndrome it is mandatory that the woman has two positive tests at least 12 weeks apart for either lupus anticoagulant or anticardiolipin antibodies of immunoglobulin G and/or immunoglobulin M class present in a medium or high titre over 40 g/l or ml/l,or above the 99th percentile).

In the detection of lupus anticoagulant, the dilute Russell's viper venom time test together with a platelet neutralisation procedure is more sensitive and specific than either the activated partial thromboplastin time test or the kaolin clotting time test. Anticardiolipin antibodies are detected using a standardised enzyme linked immunosorbent assay.

Exclusion Criteria:

  1. Age above forty years old .
  2. Intrauterine abnormalities (as assessed by ultrasound, hysterosonography, hysterosalpingogram, or hysteroscopy).
  3. Fibroids distorting uterine cavity .
  4. Abnormal parental karyotype .
  5. Other identifiable causes of recurrent miscarriages (tests initiated only if clinically indicated) e.g., diabetes, thyroid disease and systemic lupus erythematosus (SLE).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01661439

Contacts
Contact: Alaa Mahmoud Ismail, M.D +201000459514 dr.alaa_ismail@yahoo.com
Contact: Hassan salah Kamel, M.D +201006623455 hkamelhkamel@yahoo.com

Locations
Egypt
Women Health Hospital Recruiting
Assiut, Egypt
Contact: HASSAN S KAMEL, MD    +2010066436    hkamelhkamel@yahoo.com   
Principal Investigator: Alaa M Ismail, MD         
Sponsors and Collaborators
Woman's Health University Hospital, Egypt
  More Information

No publications provided

Responsible Party: alaa eldeen mahmoud ismail, MD, Woman's Health University Hospital, Egypt
ClinicalTrials.gov Identifier: NCT01661439     History of Changes
Other Study ID Numbers: PCTRPL, preconceptional heparin in APS
Study First Received: July 25, 2012
Last Updated: June 20, 2014
Health Authority: Egypt: Institutional Review Board

Keywords provided by Woman's Health University Hospital, Egypt:
Recurrent miscarriages
recurrent pregnancy loss
aps
anti coagulants in pregnancy

Additional relevant MeSH terms:
Antiphospholipid Syndrome
Fetal Death
Syndrome
Autoimmune Diseases
Death
Disease
Immune System Diseases
Pathologic Processes
Pregnancy Complications
Dalteparin
Heparin, Low-Molecular-Weight
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014